Clinical Evaluation of the Safety and Performance  of 
Fractional Radiofrequency  for the Treatment and 
Reduction  of Acne Scarring   
Protocol Identifying Number:  VI1018 
Principal Investigator:   [INVESTIGATOR_124]. Steph en Eubanks 
Funded by : [CONTACT_484523]: 2.[ADDRESS_622737] Toronto, ON  M2J 1R4  
Tel. 888 -907- 0115  
Email: [EMAIL_3066]  
 
 
_______________ _______________                       _ ____ 13/NOV /2018_____ __ 
 Signature [CONTACT_484542] : (DD/MMM/YYYY)  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October 31 , 2018 
  1 Table of Contents  
STATEMENT OF COMPLIANCE  ............................................................................................................................. 4 
PROTOCOL SUMMARY  ........................................................................................................................................... 6 
SCHEMATIC OF  STUDY DESIGN  .......................................................................................................................... 7 
1 KEY ROLES .................................................................................................................................................... 7 
2  INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE ........................ 8 
2.1 Background Informat ion ...................................................................................................................... 8 
2.2 Rationale  ............................................................................................................................................... 8 
2.3 Potential Risks and Benefits  ..............................................................................................................  9 
2.3.1  Know n Potential Risks  ..................................................................................................... 9 
2.3.2  Known Potential Benefits  ................................................................................................ 9 
3 OBJECTIVES AND PURPOSE .................................................................................................................... 9 
4 STUDY DESIGN AND ENDPOINTS  ......................................................................................................... 10 
4.1 Description of the Study Design  ...................................................................................................... 10 
4.2.1  Primary Endpoint  ............................................................................................................ 10 
4.2.2  Secondary Performance Endpoints  ............................................................................. 10 
4.2.3  Safety Endpoints  ............................................................................................................ 10 
5 STUDY ENROLLMENT AND WITHDRAWAL  ......................................................................................... 10 
5.1 STUDY POPULATION  ...................................................................................................................... 10 
5.2 Participant Inclusion Criteria  ............................................................................................................ 10 
5.3 Participant Exclusion Criteria  ........................................................................................................... 10 
5.4 Strategies for Recruitment and Retention ......................................................................................  11 
5.5 Participant Withdrawal or t ermination  ............................................................................................. 11 
5.5.1  Reasons for Withdrawal or Termination  ..................................................................... 11 
5.5.2  Handling of Participant Withdrawals or termination  .................................................. 12 
5.6 Premature Termination or Suspension of Study  ........................................................................... 12 
6 INVESTIGATIONAL DEVICE ..................................................................................................................... 13 
6.1 Investigational device and Control Description  ............................................................................. 13 
6.1.1  Acquisition  ....................................................................................................................... 13 
6.1.2  Device Specific Considerations  ................................................................................... 13 
6.2 Investigational device Accountability Procedures  ......................................................................... 14 
7 STUDY PROCEDURES AND SCHEDULE  .............................................................................................. 14 
7.1 Study Procedures/Evaluations  ......................................................................................................... 14 
7.1.1  Study specific procedures  ............................................................................................. 14 
7.2 Laboratory Procedures/Evaluations  ................................................................................................ 14 
7.2.1  Clinical Laboratory Evaluations  .................................................................................... 14 
7.2.2  Other Assays or Procedures  ........................................................................................ 14 
7.3 Study Schedule  .................................................................................................................................. 14 
7.3.1  Enrollment/Screening  .................................................................................................... 14 
7.3.2  Baseline Visit  .................................................................................................................. 15 
7.3.3  Treatment Visits  .............................................................................................................  15 
7.3.4  Follow Up Visits  ..............................................................................................................  18 
7.3.5  Early Termination Visit  .................................................................................................. 18 
7.3.6  UNSCHEDULED Visit  ................................................................................................... 18 
7.3.7  Schedule of Events Table  ............................................................................................. 19 
7.4 Justification for Sensitive Procedures  ............................................................................................. 19 
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October 31 , 2018 
  2 7.5 Concomitant Medications, Treatments, and Procedures  .............................................................  19 
7.6 Prohibited Medications, Treatments, and Procedures  .................................................................  20 
7.7 Prophylactic Medications, Treatments, and Procedures  .............................................................  20 
7.8 Rescue M edications, Treatments, and Procedures  ..................................................................... 20 
8 ASSESSMENT OF SAFETY ...................................................................................................................... 20 
8.1 Specification of Safety Parameters  .................................................................................................  20 
8.1.1  Definition of  Adverse Events (AE) and adverse device effect (ADE)  ..................... 20 
8.1.2  Definition of Serious Adverse Events ( SAE)  .............................................................. [ADDRESS_622738] (SADE)  .................................................. 21 
8.1.4  Definition of Device deficiency  .....................................................................................  21 
8.2 Classification of an Adverse Event .................................................................................................. 22 
8.2.1  Severity of Event  ............................................................................................................ 22 
8.2.2  Relationship to INVESTIGATIONAL DEVICE ........................................................... 22 
8.2.3 Expectedness  ................................................................................................................. 23 
8.3 Time Period and Frequency for Event Assessment and Follow -Up .......................................... 23 
8.4 Reporting Procedures  ....................................................................................................................... 24 
8.4.1  Adverse Event Reporting  .............................................................................................. 24 
8.4.2  Serious Adverse Event Reporting  ............................................................................... 24 
8.4.4  Reporting of Pregnancy  ................................................................................................ 25 
8.5 Study Halting Rules  ........................................................................................................................... 25 
8.6 Safety Oversight  ................................................................................................................................ 25 
8.7 Training Requirements  ...................................................................................................................... 25 
9 CLINICAL MONITORING ............................................................................................................................ 25 
10 STATISTICAL CONSIDERATIONS  .......................................................................................................... 26 
10.1  Statistical and Analytical Plans  ........................................................................................................ 26 
10.2  Statistical Hypotheses  ....................................................................................................................... 26 
10.3  Analysis Datasets  .............................................................................................................................. 26 
10.4  Description of Statistical Methods  ................................................................................................... 27 
10.4.1  General Approach  .......................................................................................................... 27 
10.4.2  Analysis of the Primary Efficacy Endpoint(s)  .............................................................  27 
10.4.3  Analysis of the Secondary Endpoint(s)  ....................................................................... 28 
10.4.4  Safety Analyses  ..............................................................................................................  28 
10.4.5  Adherence and Retention Analyses  ............................................................................ 29 
10.4.6  Baseline Descriptive Statistics  .....................................................................................  30 
10.4.7  Planned Interim Analyses  ............................................................................................. 30 
10.4.9  Multiple Comparison/Multiplicity ................................................................................... 30 
10.4.10  Tabulation of Individual Response Data  ..................................................................... 30 
10.4.11  Exploratory Analyses  ..................................................................................................... 30 
10.5  Sample Size  ....................................................................................................................................... 30 
10.6  Measures to Minimize Bias  ..............................................................................................................  31 
10.6.1  Enrollment/ Randomization/ Masking Procedures  .................................................... 31 
10.6.2  Evaluation of Success of Blindi ng ............................................................................... 31 
10.6.3  Breaking the Study Blind/Participant Code  ................................................................ 31 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  ................................... 32 
12 QUALITY ASSURANCE AND QUALITY CONTROL  .............................................................................. 32 
13 ETHICS/PROTECTION OF HUMAN SUBJECTS  ................................................................................... [ADDRESS_622739]  .................................................................................................................................  33 
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October 31 , 2018 
  3 13.2  Ethics committee and competent authorities  ................................................................................. 33 
13.3  Informed Consent Process  ............................................................................................................... 33 
13.3.1  Consent/assent and Other Informational Documents Provided to Participants  .... [ADDRESS_622740] OF ABBREVIATIONS  ..................................................................................................................................... 38 
 
 
 
 
  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October [ADDRESS_622741] version of the D eclaration of Helsinki 
(2013), ISO [ZIP_CODE]:2011 (Clinical investigation of medical devices for human subjects -  Good clinical 
practice ), Medical Devices Directive 93/42/EEC, MEDDEV 2.7/3 , [LOCATION_002] (US) Code of Federal 
Regulations (CFR) applicable to clinical studies (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 
312, and/or 21 CFR Part 812)  and any of the applicable regional or national regulations pertaining to 
conduct of a clinical investigation of a medical device.  
The clinical investiga tion shall not begin until the required approval or favorable opi[INVESTIGATOR_10363] ( EC) has been obtained and, if applicable, any local or  national regulatory authority approvals 
or notifications have been obtained.  
Any additional requirement s imposed by [CONTACT_484524].  
The Sponsor has obtained clinic al investigation insurance that will cover expenses in the event of any 
physical injury resulting from research procedures.  
  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October 31 , 2018 
  6  
PROTOCOL SUMMARY  
 
TITLE  Clinical Evaluation of the Safety and Performance of Fractional Radiofrequency  
for the Treatment and Reduction of Acne Scarring   
SUMMARY  Prospective,  single centre , evalua tor-blind study of the safety and performance 
of fractional  radiofrequency ( RF) for the treatment  and reduction of acne 
scarring .  The s tudy will  evaluate [ADDRESS_622742] one treatment.  
OBJECTIVES  The objective of this clinical study is to evaluate the safety and performance of 
fractional RF for the treatment and reduction of acne scarring . 
ENDPOINT  Primary performance endpoints  
• Improvement  in acne  scarring  at [ADDRESS_622743] -treatment  
compared  to baseline  as assessed  by [CONTACT_484525]  
• Subjects’ assessment of satisfaction with the treatment using a Subject 
Satisfaction Scale at [ADDRESS_622744] -treatment.  
 
Safety endpoints  
• Subject’s assessment of discomfort and pain after treatment s as 
measured by a 10 cm visual analog scale (VAS)  and Tolerability Scale  
• Subjects experiencing a treatment -related adverse event ( AE) by [ADDRESS_622745] -Market  
NUMBE R OF SITES  1  
DESCRIPTION OF 
DEVICE  The Venus Viva™ fractional RF applicator  has been shown in clinical studies to 
improve various skin conditions related to aging and alter collagen structures 
such as wrinkles, rhytids  and scars .  The applicator offers the option of 80 and 
160 pin tips, to deliver nano fractional RF energy to the treatment  site when 
used with the Venus Viva™ or Venus Versa™ system . 
STUDY DURATION  Approximately 12 months  
PARTICIPANT 
DURATION  6 months  
 
 
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October 31 , 2018 
  7  
SCHEMATIC OF STUDY DESIGN  
 
Screeni ng Visit  
 Screen Potential Subjects By [CONTACT_10385];  
Obtain Informed Consent , Medical History, Administer Test Spot, Physical 
Exam  and Demographics  
  
Visit 1 – Baseline /Tx [ADDRESS_622746] Spot for AEs, C oncomitant Medication, Photographs ,  
Administer Initial Study Treatment, 10 cm Pain VAS  and Tolerability Scale  
  
Visit 2 -Tx2 
Week 4   
(+/- 1 week ) AEs, Concomitant Medication , Administer Study Treatment , 10 cm Pain VAS 
and Tolerability Scale  
  
Visit 3 -Tx3 
Week 8   
(+/- 1 week )  AEs, Concomitant Medication , Administer Study Treatment , 10 cm Pain VAS  
and Tolerability Scale  
  
Visit 4 – FU1 
[ADDRESS_622747] - final 
treatment  
(+/- 1 week)  AEs, Concomitant Medication, Photographs, Subject  Satisfaction  Scale, 
Treatment Eva luation Questionnaire  
  
Visit [ADDRESS_622748] -final 
treatment  
(+/- 1 week)  AEs, Concomitant Medication, Photographs,  Subject  Satisfaction Scale, 
Treatment Evaluation Questionnaire  
  
1 KEY ROLES  
 
Stephen Eubanks, MD  
Leavitt Medical Associates of [LOCATION_012] d/b/a Ameriderm Research  
[ADDRESS_622749].  
Suite 2  
Port Orange, FL [ZIP_CODE] 
Tel. 386 -322- 8310 
Email  : drseubanks @leavittmgt .com  
 
 
Paul Cardarelli 
Senior Director of Product Marketing and Clinical Affairs  
Venus Concept  
[ADDRESS_622750] Toronto, Ontario, M2J 1R4  
CANADA  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October 31 , 2018 
  8 Tel. 888 -907- 0115  
Email: [EMAIL_3066]  
 
2  INTRODUCTION: BAC KGROUND INFORMATION AND SCIENTIFIC RATIO NALE  
 
2.[ADDRESS_622751]-acne sequelae2.  Current  
procedures such as chemical or lase r peels, dermabrasion or nonablative laser resurfacing are usually 
associated with prolonged recovery times as well as arduous side effects1. To circumvent these issues, 
the use of non -invasive , nonsurgical approaches that do not require downtime are becoming the 
preferred method of choice for patients seeking cosmetic improvements.  An innovative technique that 
was introduced to reduce facial wrinkles and rhytides is known as radiofrequency (RF ). 
Treatment of acne scars with f ractional RF therapy has been shown to promote remodeling of the 
dermis to replace acne  scar-associated irregularities  with a  more normal architecture, particularly in the 
case of elastic fibers and  over -deposition of elast in6. 
The premise behind RF techno logy is dermal heating,  which initiates the denaturation of collagen and 
the stimulation of neocollagenesis through the  induction of inflammation that leads to the production of 
fibroblasts at the heated area and the  subseq uent development of new collagen.2 RF energy produces 
an oscillating electrical current that can penetrate the dermis and hypodermal tissues without disturbing 
the epi[INVESTIGATOR_3915]-dermal barrier. The generation of the heat energy is the result of the natural res istance 
that dermal tissue has to  the movement of ions with an electromagnetic field. Accordingly, the 
oscillating electrical current causes collisions between charged ions that are transformed into heat 
energy.2 The production of heat energy through RF ty pi[INVESTIGATOR_484514], coag ulation, and skin 
resurfacing.    
Mono -polar RF devices were used initially for facial treatments, and although the results appeared to be 
promising, this approach was associated with serious pain as well as the high inciden ce of adverse 
events including se cond -degree burns that are caused by [CONTACT_484526].5 Bipolar and multi -polar RF devices allow the heat energy to be distributed more evenly 
with less depth-penetration, thereby [CONTACT_484527] a patient’s skin type.   
Therefore, RF techniques that improve the ability to control the ablation a nd coagulation of the skin can 
result in  acne scar  treatment consistency that will provide more flexibility to treat a wider variety of skin 
conditions.   
2.[ADDRESS_622752] udies to improve skin laxity, and to treat various 
skin conditions related to aging and alternate collagen structures such as wrinkles, rhytids  and scars.   
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October 31 , 2018 
  9 The objective of this clinical study is to evaluate the safety and performance of fractional  RF for the 
treatment of  acne scarring  
The use of the Venus Viva ™ applicator  and system has been determined to present non -significant risk 
in accordance with 21 CFR 812.3 for the intended use in this study, because the device is not:  
• Intended as an implant;  
• Purported or represented to be for use supporting or sustaining human life;  
• Substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise 
preventing impairment of human health  
• Otherwise present ing a potential for serious risk to  the healt h, safety, or welfare of a subject.  
This study will be conducted in compliance with the protocol and according to Go od Clinical Practice 
(GCP) standards. 
2.[ADDRESS_622753] -treatment , excessive skin redness (erythema) and/or swelling 
(edema) , in-grown hairs , damage to natural skin texture (crust, blister, burn) , change of pi[INVESTIGATOR_371] 
(hyper - and hypo -pi[INVESTIGATOR_371])  and scarring . Treatment of hair -bearing areas in male patients may 
result in some damage to the follicles and subsequent loss of hair.  Avoid the beard area and other hair - 
growing zones if the patient does not w ish to experience hair growth reduction.   
Further information about r esidual risks associated with the device  and with participation  in the clinical 
investigation are reported in the device User Manual . 
Residual risks will be mitigated as follows: 
− Selectio n of an i nvestigator with experience in the  therapeutic area of the clinical investigation 
− Investigator  and site staff will have already undergo ne training prior to patients’ enrollment  
− Prior to  the first procedure, the investigator and site staff will un dergo a re -training session by 
[CONTACT_484528]  
− Patients will be rigorously screened prior to their enrollment  
− Patients will be rigorously followed over the course of the study  
 
2.3.[ADDRESS_622754] agrees to participate in this study, he/ she will be contributing to the understanding of the 
device’s impact and the biological processes that are occurring regarding  acne scar  formation . This 
understanding may lead to optimization of the tr eatment with this device  for these indications .  In 
addition,  the subject may benefit from improvement in acne scar  appearance in the treated area s. 
3 OBJECTIVES AND  PURPOSE  
This clinical study is being conducted  to evaluate the safety and performance of nano fractiona l RF for 
the treatment and reduction of acne scarring . Total expected duration of the clinical investigation  is 
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October 31 , 2018 
  10 twelve months  (enrolment period of 6  months, follow -up period of 6 months ), while individual subject 
participation will take  approximately  6 mon ths. 
4 STUDY DESIGN AND ENDPOINTS  
 
4.1 DESCRIPTION OF T HE STUDY DESIGN  
This is a  prospective, evaluator -blind study of the safety and performance of fractional  RF for the 
treatment  and reduction  of acne scarring . 
4.2.1 PRIMARY ENDPOINT  
• Improvement in acne scarring  at [ADDRESS_622755] -intervention compared to baseline 
as assessed by [CONTACT_484529]  (GAIS).  
4.2.2 SECOND ARY PERFORMANCE E NDPOINTS  
 
• Subjects’ assessment of satisfaction with the treatment using a Subject   Satisfaction Scale at [ADDRESS_622756] -treatment.  
4.2.3  SAFETY ENDPOINTS  
• Subjects ’ assessment of discomfort and pain  after treatments  as measured by a 10 cm visual 
analog scale (VAS).  
• Subjects exper iencing a treatment -related adverse event (AE) by [ADDRESS_622757] been treated according to study protocol .   
5.2 PARTICIPANT  INCLUSION CRITERIA  
1. Healthy , male or female subjects  22 years of age  or over  who are seeking treatment and 
reduction of  their facial acne scarring . 
2. Able to read, und erstand and voluntarily provide written Informed Consent . 
3. Able and willing to comply with the treatment/follow -up schedule and requirements . 
4. Women of child-bearing age are required to be using a reliable method of birth control at least [ADDRESS_622758] at baseline.  
5.3 PARTICIPANT  EXCLUSION CRITERIA  
1. Implantable defibrillators, cardiac pacemakers, and other metal implants  
2. Subjects with any implantable metal device i n the treatment area  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October 31 , 2018 
  11 3. Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body 
(e.g. cochlear implant).  
4. Permanent implant in the treated area, such as metal plates and screws, or an injected chemical 
substance.  
5. Curren t or history of any kind of cancer, or pre -malignant moles.  
6. Severe concurrent conditions, such as cardiac disorders.  
7. Pregnancy or intending to become pregnant during the study and nursing.  
8. Impaired immune system due to immunosuppressive diseases, such as A IDS and HIV, or use of 
immunosuppressive medications. 
9. History of diseases stim ulated by [CONTACT_10388], such as recurrent herpes simplex in the treatment area ; 
may be enroll ed only after  a prophylactic regime  has been followed for 2 weeks or longer prior 
to enrollme nt, or according to Investigator’s discretion .  
10. Poorly controlled endocrine disorders, such as diabetes.  
11. Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash.  
12. History of skin disorders, such as keloids, abnormal wound heal ing, as well as very dry and 
fragile skin.  
13. History of bleeding coa gulopathies, or use of anticoagulants  (excluding daily aspi[INVESTIGATOR_248]) . 
14. Facial dermabrasion, facial resurfacing, or deep chemical peeling within the last three months, if face is treated.  
15. Use of is otretinoin (Accutane®) or other retinoids within six months prior to treatment or as per 
physician’s discretion .  
16. Use of non -steroidal anti-inflammatory drugs (NSAIDS, e.g. ibuprofen -containing agents) one 
week before and after each treatment session.  
17. Any surgical procedure in the treatment area within the last six months or before complete 
healing.  
18. Treating over tattoo or permanent makeup.  
19. Excessively tanned skin from sun, tanning beds or tanning creams within the last two weeks.  
20. As per the practitioner's discretion, refrain from treating any condition which might make it 
unsafe for the patient.   
5.[ADDRESS_622759] been treated according to the study 
protocol .  It is anticipated that it will take up to twelve months  to complete the study.  Subjects  will  
primarily be recruited from the investigator’s practice .  Any advertising campaigns and materials will be 
reviewed and approved by [CONTACT_10389] I nstitutional Review Board ( EC or IRB) before 
implementation.  Due to the long duration of the study, subjects will be contact[CONTACT_10390] a regular basis to  enhance retention.  
5.[ADDRESS_622760] d rops out of the study or is withdrawn from the study, the End of 
Study /Early Discontinuation  CRF form should be completed.  On the discontinuation  page,  the 
Investigator should record the date of the withdrawal and the reason f or withdrawal.   
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October [ADDRESS_622761]’s  participation in the study if:  
• Any clinical adverse event (AE), laboratory abnormality, or other medical condition or situation 
occurs such that continued participation in the study would not be in the best interest of the 
subject.  
• The subject  meets an exclusion criterion (either newly developed or not previously recognized) 
that precludes further study participation.  
5.5.[ADDRESS_622762] an exit visit  (final study visit, see 
section 7.3.5)  to withdrawn patients , and to  undertake protocol -specified safety follow -up procedures 
to capture AEs, serious adverse events (SAEs) an d device deficiencies.   
5.6 PREMATURE TERMINATIO N OR SUS PENSION OF STUDY  
The sponsor may suspend or prematurely terminate this study at  the investigation site fo r significant and 
documented reasons. 
 
A principal investigator, EC/IRB, or regulatory authority may suspend or prematurely terminate 
participation in the study at the investigation site for which they are responsible.  
 
If suspi[INVESTIGATOR_10366], or when so instructed by [CONTACT_1383]/IRB 
or regulatory authorities, the sponsor shall suspend the clinical investigati on while the risk is assessed.  
The sponsor shall terminate the study if an unacceptable risk is confirmed. 
 
The sponsor shall consider terminating or suspending the participation of the  investigation site or 
investigator in the study if monitoring or audi ting identifies serious or repeated deviations on the part of 
an investigator.  If suspension or prematur e termination occurs, the terminating party shall justify its decision in writing 
and promptly inform the other parties with whom they are in direct co mmunication. The principal 
investigator [INVESTIGATOR_484515] r eceived from either the 
EC/IRB or the regulatory authority.  
 If, for any reason, the sponsor suspends or prematurely terminates the study at the invest igation site, the 
sponsor shall inform the responsible regulatory authority as appropriate and ensure that the EC/IRB is 
notified, either by [CONTACT_458] [INVESTIGATOR_10368].  If the suspension or premature termination 
was in the interes t of sa fety, the sponsor shall inform all other principal investigators.  
 
If suspension or premature termination occurs,  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October 31 , 2018 
  13 a) the sponsor shall remain responsible for providing resources to fulfil the obligations from the 
clinical investigative plan  and existin g agreements for following up the subjects enrolled in the 
study, and  
b) the principal investigator [INVESTIGATOR_484516], if appropriate  
 In case of early termination, final study activities acc ording to the protocol, including the follow up visits 
and proc edures to assess the safety and efficacy of the device will be conducted, regardless of the 
sponsor's interest in the study.  Follow -up activities will be conducted so that device deficiencies can be 
identified,  and appr opriate safety measures can be implemented.  
 At the completion or termination of the study, the Investigator will return all remaining clinical supplies 
to Sponsor along with a copy of the device supply and inventory records. 
 
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants  (examples of 
findings that might trigger a safety review are the number of SAEs overall, the number of occurrences of a particular ty pe of SAE, severe AEs/reactions, or increased frequency of events  – 
refer to section  8.5 STUDY HALTING RULES . 
• Demonstration of performance  that would warrant stoppi[INVESTIGATOR_007]  
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or evaluable  
• Determination of futility  
Study may resume once concerns about safety, protocol compliance, data quality are addressed and 
satisfy the sponsor, EC / IRB and/or regulatory authorities . 
6 INVESTIGA TIONAL DEVICE  
 
6.1 INVESTIGATIONAL DEVIC E AND CONTROL DESCRIPTION  
 
6.1.1  ACQUISITION   
If the investigative  site does not own a Venus Viva™,  a device  will be provided  by [CONTACT_456].  An 
activation code will be required to activate the device  (not applicabl e if the site owns t he device) .  This 
code will be pr ovided to the investigative site once  all regulatory and EC /IRB approvals are in place and 
the site has received training for both the device and the study  (if applicable) .  
6.1. 2 DEVICE SPECIFIC CONSIDE RATIONS  
• Device model(s)  - Venus Viva ™ Applicator   
• Device settings and programming –  Ablation and Coagulation  Mode ; 180-2 80 volts, 5-30 ms 
pulse duration  
• Duration of exposure and frequency –   
o For all subjects - treatment is monthly for 3 months .   
The Venu s Viva™ applicator is a non -invasive medical aesthetic device, intended for use in dermatologic 
and general surgical procedures, requiring ablation and resurfacing of the skin.   
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October 31 , 2018 
  14 The handheld applicator  utilizes  disposable tips, the tip options  include 80 pin and 160 pin tips, 8x20 mm 
in size  to deliver the Multi Polar Radiofrequency (RF)  to the skin .  The Venus Viva ™ applicator  may be 
used with the Venus Viva ™ and Venus Versa ™ systems.  Further  details about t he Venus Viva ™ 
Applicator can be found  in the  device User Manual . 
6.2 INVESTIGATIONAL DEVICE  ACCOUNTABILITY PROC EDURES  
If the device is supplied by [CONTACT_456], t raceability shall be achieved during and after the clin ical 
investigation by [CONTACT_10392].   Disposal tips will be provided 
by [CONTACT_456]. 
 
7 STUDY PROCEDURES AND SCHEDULE 
 
7.1 STUDY PROCEDURES/EVA LUATIONS  
7.1.1  STUDY SPECIFIC  PROCEDURES   
The following procedures and evaluations will be done as part of the study : 
Demographics  
Medical /surgical history (obtained by [CONTACT_10393]/ or medical records)  
Physical examination  
Assessment of eligibility  
Photographs   
Blinded assessment  
Administration of questionnaires and scales for blinded reviewer and patient -reported outcomes  
Adverse event recording  
Concomitan t medications  
7.2 LABORATORY PROCEDURES/EVALUATIONS    
 
7.2.[ADDRESS_622763] to be performed within 24 hours of study intervention with results available prior 
to administration of treatment.    
7.2.2  OTHER  ASSAYS OR P ROCEDURES  
None.  
7.3 STUDY SCHEDULE  
 
7.3.1  ENROLLMENT/ SCREENING  
  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October 31 , 2018 
  15 Screening  and Enrolment  Visit  (Day -7 to -2)  
 
If the subject meets the preliminary study criteria , the study doctor, and/or his /her  designee, will obtain 
an informed consent from the subject  prior to any study procedure, clearly indicating his/ her 
understanding of the requirements and possible risks associated with study participation and other 
applicable treatment options.  Subjects will receive a unique identifying number that will be compo sed 
of a two -digit site number and a two -digit subject number in sequence.  This unique identifier will be 
used throughout the entire study and will be entered in the subject's case report form (CRF).  
During the first visit, the study investigator, and/or  his/her  designee, will screen the subject for eligibility 
to participate i n the clinical study using the i nclusion/e xclusion criteria.  A negative urine pregnancy test 
will be obtained (in patients of child -bearing potential) .  During screening,  the study  doctor will review 
the subject's medical /surgical history , demographics, conduct a physical exam  and examine the subject's 
targeted treatment area to ensure that it meets the study criteria.  The subject will complete screening 
and the treatment  will be s cheduled.  
Test Spots  
A small test spot will be performed in a non -conspi[INVESTIGATOR_10370], prior to the first 
complete session. Test spots are performed to establish the following requirements:  
• Confirm the patient's suitability fo r treatmen t:  
o For skin types I-III,  wait 24 -48 hours  
o For skin type IV -VI, wait 5 – 7 days  before assessing the skin response  
• Establish and confirm treatment parameters:   If the desired endpoint of erythema and edema –  
in a tip-shaped pattern –  has not been achieved  within [ADDRESS_622764] spot whenever changing 
parameters.   
7.3.2  BASELINE  VISIT  
Basel ine Visit (Visit 1  - Day 0 ) 
Subjects will return to the clinic [ADDRESS_622765] of three 
treatments  (see 7.3.3) .  The subject’s eligibility status at this timepoint according to the 
inclusion/exclusion criter ia will be re -confirmed.  Adverse events  from the test spot, and any changes to 
concomitant medications will be r ecorded.  
 
7.3.3  TREATMENT VISITS   
Beginning with the Baseline visit (Visit 1 ), subjects will receive a total of 3 treatments approximately 3-5 
weeks apart .  The left and right  side of the face will be treated and assessed as independent sites, and 
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October 31 , 2018 
  16 the same applicator tip configuration will be used to treat both sides at all 3 treatment visits.  Adverse 
events and any changes to concomitant medic ations will be recorded at these visits . 
Subjects will receive treatment as described below.   Following treatment, the investigator will examine 
the treated area and report immediate and short term response.  Subjects will complete the 10 cm discomfort/pai n VAS and Tolerability Scale immediately after treatment.    
The investigator will examine the treated areas and report immediate and short term response ([ADDRESS_622766] -treatment) (pain during treatment, hemorrhage, burn, erythema, edema, purpura) using a  
5-point scale: 1=none; 2=trace; 3=moderate; 4=marked; 5=severe.    
The normal response to these treatments is transient erythema and edema. If any other side effects occur, as indicated in the protocol, they must be recorded.  
Visit 1 – Day [ADDRESS_622767] spot evaluation from the 
screening  visit, treatment parameters will be selected by [CONTACT_093].   In addition to the treatment, 
concomitant medications, photographs and the pain VAS an d Tol erability Scale are to be completed by 
[CONTACT_102].  
Visit 2 – Week 4 (+/- 7 days)  
The Subject is to return to the clinic for their second of the three treatments.  In addition to the treatment, concomitant medications, AEs and the pain VAS and Tolerab ility Scale are to be completed 
by [CONTACT_102].  
Visit 3 -- Week 8 (+/- 7 days)  
The Subject is to return to the clinic for their final treatment.  In addition to the treatment, concomitant medications, AEs and the pain VAS and Tolerability Scale are to be c omple ted by [CONTACT_102].  
 
Treatment  
Subjects will be asked to present to the clinic clean shaven prior to receiving treatment .  There  should 
be no lotion, make-up, perfume, powder, or bath/shower  oil present on the skin in the area to be 
treated.  Ensure th at the skin is completely dry during the entire treatment. If the skin moistens during 
treatment (i.e. perspi[INVESTIGATOR_1516], etc.) re-wipe the skin with an alcohol pad and ensure that the skin is 
completely dry before continuing the treatment.  
Depending upon the s ubject’s sensitivity to the test spot administration, a topi[INVESTIGATOR_484517]’s discretion.  This 
topi[INVESTIGATOR_10372].  
Set the treatment parameters  to desired treatment mode and select the appropriate tip (160 pin or 80 
pin tip) .  The selected tip will be utilized for all of the specific patient’s subsequent treatments.  Set the  
desired energy level according to the skin type, severity of the treated condition, treatment area, bone 
proximity, etc.  Set conservative parameters from a test spot for the first treatment, and then gradually 
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October [ADDRESS_622768] with the skin.  Emit a pulse by [CONTACT_10394]'s trigger; this will create a tip-shaped 
pattern on the patient's skin that will appear 1 -2 minutes later. Move the applicator to an adjacent spot 
on the skin overlappi[INVESTIGATOR_10373] 10% and emit another pulse (not applicable to the test spot). There should be 
no untreated gaps betwee n the puls es.  
Examine the treated area. The immediate responses, indicative of the desired effect, are erythema and 
edema in the immediate area of the tip -shaped pattern and possibly also around it. The edema usually 
appears 1 -2 minutes after pulsing and reaches it s peak (of up to moderate edema) within 30 minutes. It 
should be noted that erythema is not easily noticeable –  if at all –  in darker skin types. Therefore, the 
edema will be more prominent in these patients. After completing a full pass on the entire trea tment 
area, if untreated patches of skin are apparent, re -treat these patches as per the following procedure:  
i. Wipe the untreated patch of skin with a dry gauze pad.  
ii. Treat the untreated patches of skin as normally.  
Fine -tuning o f the parameters shoul d be done before proceeding to treatment of the entire sub -area 
with the selected parameters. The applicator tip should be placed on the skin, a pulse emitted, then lifted and moved to an adjacent spot of the skin. The emitted pulses should create tip -shap ed patterns. 
Leave, no untreated gaps between the pattern marks, while also being careful not to overlap the treated 
zones. The parameters can be modified during subsequent visits, as per the practitioner's discretion.  
Post -Treatment Care  
Post -treatment co oling is not necessary.  In the event of post -treatment discomfort, it is recommended 
to cool the treated area immediately with air cooling.  Cold (not frozen) packs may also be used. 
Blistered or ulcerated skin can be treated with a prescribed cream. Tiny  scabs of less than [ADDRESS_622769] -treatment and may remain for several days. The scabs 
should not be touched or scratched even if they itch, and should be allowed to shed off naturally. 
Blistered or ulcerated skin can be treated with a prescribed antibiotic ointment or burn treatment cream 
as per physician's discretion.  During the first two days following treatment, care should be taken to 
prevent trauma to the treated site.  Hot baths, massage, etc.  should be avoided. Th e skin should be kept 
clean to avoid contamination or infection.  Any mechanical or thermal damage to the area must be 
avoided.  Moisturizer may be applied only 24 hours after each treatment, and then should be applied 
regularly throu ghout the course of the treatment.  Make-up may be applied only 24 hours after each 
treatment if desired, unless an unwanted reaction occurs in the area.  Generally, 24 hours after 
treatment, patients may use regular soaps, but not scrub soaps or exfoliant s. The patient should use a 
high -factor sunscreen (at least 30 SPF) and protect the treated area from sunlight for at least one month 
after the treatment.  Tanning of any sort (sun exposure, tanning beds, and artificial sunless tanning 
lotions) is not allo wed in the treated are as during the entire course of the treatment.  Tanning after 
treatment may cause hyperpi[INVESTIGATOR_371].  
Photography  
Photographs will be taken prior to first treatment and throughout the study according to specified time points detailed i n the Schedule of Even ts Table (section 7.3.7), utilizing standard scientific equipment.     
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October [ADDRESS_622770] naming scheme.  
7.3.4  FOLLOW UP VISITS  
Visit 4 – [ADDRESS_622771] Final Treatment (+/ - 7 days)  
Subjects will return to the clinic [ADDRESS_622772]  Satisfaction  Scale and 
Treatment Evaluation questi onnaire.  
Photographs of the treated area will be taken as described in section 7.3.3 . The photographs will be sent 
to the blinded independent reviewer for the Global Aesthetic Improvement Scale (GAIS)  assessment .   
Visit 5 – [ADDRESS_622773] Final Tr eatment (+/ - 7 days)  
Subjects will return to the clinic for a final stud y visit [ADDRESS_622774] all reportable events with start dates occurring any time after informed consent is obtained until 
7 (for non -serious AEs) or 30 days (for SAEs) after the last day of study participation.  
7.3. [ADDRESS_622775] be completed .  
Adverse events and the reason for early termination will be recorded.  
7.3.6  UNSCHED ULED VISIT  
If an unscheduled visit occurs, the reason for the u nscheduled visit will be documented. I f the 
unscheduled visit is the result of an adverse event, the event will be recorded on the adverse event CRF.  
 
  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October 31 , 2018 
  19  
7.3.7  SCHEDULE OF EVENTS TABLE  
 
Procedures  
Screening  Visit  
(Day -7  to -2) 
Baseline/Treatment 1  
(Visit  1, Day 0)  
Treatment 2  
(Visit 2, Week 4 (+/ - 7 days)  
Treatment 3  
(Visit 3, Week 8 (+/ - 7 days)  
Follow -up 1 
(Visit 4, [ADDRESS_622776] -Final 
Treatment +/ - 7 days)  
Follow -up 2  
(Visit 5, [ADDRESS_622777] -Final 
Treatment +/ - 7 days))  
Informed consent  X      
Inclusi on/exclusion criteria  X X     
Demographics  x      
Medical history  X      
Physical exam  X      
Concomitant medication  X X X X X X 
Urine pregnancy test  X      
Test Spot  X (X) (X) (X)   
Photographs   X   X X 
Administer Treatment   X X X   
Adverse event  evaluation   X X X X X 
Discomfort/ Pain VAS  and Tolerability Scale   X X X   
PI [INVESTIGATOR_484518] & short -term response   X X X   
Subject  Satisfaction Scale      X X 
Treatment Evaluation Questionnaire      X X 
(X) - if required  
7.4 JUSTIFICATION FOR SENSITIVE PROC EDURES  
 This is a non -life-threatening aesthetic treatment  with a low potential for serious adverse events . 
7.5 CONCOMITANT MEDICATIONS, TREATMENTS,  AND PROCEDURES  
All concomitant prescription medications taken during study participation will be recorded on the case 
report forms (CRFs).   For this protocol, a prescription medication is defined as a medication that can be 
prescribed only by a properly autho rized/licensed clinician.  Other medications to be reported in the CRF 
are concomitant over -the-counter  medications , non-prescription medications  and herbal/naturopathic 
preparations . 
  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October [ADDRESS_622778] degree burn 
or pain beyond narcotics, then the following pro cedure will be implemented:  
• Immediate triage and treatment of the patient shall be determined by [CONTACT_484530] u pon severity and type of burn identified.  
• The event will be reported to the sponsor study Director within [ADDRESS_622779] be reported on the SAE form.  
• An anonymized  copy of the patient chart a nd treatment parameters are to be forwarded to the 
sponsor study Director within 24 hours.   
The sponsor study Director will be responsible for issuing a written report to the company and the EC or 
IRB Chairman no later than 7 days from the event   
Long term follow up and care shall continue at the discretion of the treating physician.  
All patients experiencing a complication of the device will be followed a minimum of 2 years following 
the initial injury.  Longer care and observation will be at the  discre tion of the treating physician.   
All minor complications such as appearance or altered sensation, except for pain, can be reported within 30 days of patient complaint.  Both chart and treatment parameters are to be provided to the study Director an d share d with the company and EC or IRB chairman.  
8 ASSESSMENT OF SAFETY  
 
8.1 SPECIFICATION OF SAFETY PARAMETERS  
In addition to spontaneous reports of adverse events, subjects will complete a 10 cm  discomfort/ pain 
VAS and the principal investigator [INVESTIGATOR_1318] e xamine the treated area and report immediate and short term 
response. 
8.1.1  DEFINITION OF ADVERS E EVENTS  (AE)  AND ADVERSE DEVICE EFFECT (ADE)  
Adverse event means any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including  abnormal laboratory findings) in subjects, users or other persons, whether or not 
related to the  investigational medical device .
 This definition includes events related to the 
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October 31 , 2018 
  21 investigational me dical device or the comparator.  This definition in cludes even ts rela ted to the 
procedures involved.  For users or other persons, this definition is restricted to events related to 
investigational medical devices  (ISO [ZIP_CODE]: 2011) . 
Adverse device effect means any adverse event related to the use of an inves tigational medical device . 
This definition includes adverse events resulting from insufficient or inadequate instructions for use , 
deployment, implantation, installation, or operation, or any malfunction of the investigational medical 
device.  This definit ion includes any event resulting from use error or from intentiona l misuse of the 
investigational medical device (ISO [ZIP_CODE]:2011).  
8.1.2  DEFINITION OF SERIOU S ADVERSE EVENTS  (SAE)  
NOTE: The term serious is not synonymous with severity, which may be used to describe t he intensity of 
an event experienced by [CONTACT_423]).  An AE that does not meet any of the below criteria will be 
classified as non -serious.  
A serious AE  is any adverse event that:  
• led to death,  
• led to serious deterioration in the health of the subject, that either resulted in  
− a life -threatening illness or injury, or  
− a permanent impairment of a body structure or a body function, or  
− in-patient or prolonged hospi[INVESTIGATOR_059],  or 
− medical or surgical intervention to prevent life -threatening illness or injury or p ermanent 
impairment to a body structure or a body function  
• led to fetal distress, fetal death or a congenital abnormality or birth defect  
Planned hospi[INVESTIGATOR_272] a pre -existing condition, or a procedure required by [CONTACT_10396], without serious  
deterioratio n in health, is not considered a serious adverse event  (ISO [ZIP_CODE]:2011) . 
8.1.[ADDRESS_622780] ( SADE) 
This definition  include s any adverse device effect that has resulted in any of the consequences 
characteristic of a serious ad verse event .  Unanticipate d serious adverse device effect ( [LOCATION_003]DE ) is any 
serious adverse device effect which by [CONTACT_5942], incidence, severity or outcome  has not been identified 
in the current version of the risk analysis report .  Anticipated serious adve rse device effect (ASADE) is an 
effect which by [CONTACT_10397], incidence, severity or outcome has been identified in the risk analysis repor t 
(ISO14155:2011).  
8.1.[ADDRESS_622781] to its identity, q uality, durability, reliability, safety or 
performance .  Device deficiencies include malfunctions, use e rrors, and inadequate labelling (ISO 
[ZIP_CODE]:2011).  
Any Investigational Medical Device Deficiency that might have led to a SAE if a) suitable action had not 
been taken or b) intervention had not been made or c) if circumstances had been less fortunate  is 
subject to  the same reporting requirement of SAEs (MEDDEV 2.7/3 revision 3).  
 
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October 31 , 2018 
  22 8.2 CLASSIFICATION OF AN  ADVERSE EVENT  
 
8.2.1  SEVERITY OF EVENT  
For AEs not i ncluded in the protocol defined grading system, the following guidelines will be used to 
describe severity.  
• Mild  – Events require minimal or no treatment and do not interfere with the participant’s daily 
activities.  
• Moderate  – Events result in a low level of inconvenience or concern with the therapeutic 
measures.  Moderate events may cause some interference with fun ctioning.  
• Severe  – Events interrupt a participant’s usual daily activity and may require systemic drug 
therapy or other treatment. Severe events  are usually potentially life -threatening or 
incapacitating.  
8.2.2  RELATIONSHIP TO INVESTIGATIONAL DEVI CE 
The cl inician’s assessment of an AE's relationship to the investigational device  is part of the 
documentation process, but it is not a factor in deter mining what is or is not reported in the study.  If 
there is any doubt as to whether a clinical observation is a n AE, the event should be reported.  All AEs 
must have their relationship to investigational device  assessed.  In a clinical trial, the study pr oduct must 
always be suspect. To help assessment , the following guidelines are used.  
• Not Related – relation  to the device or procedure can be excluded when:  
− The event is not a known side effect of the product category the device  belongs to or of similar 
devices and procedures;  
− the event has no temporal relationship with the use of the investigational device or the 
procedures;  
− the serious event does not follow a known response pattern to the medical device (if the response 
pattern is previously known) and is  biologically implausible  
− the discontinuation of medical device application or the reduction of the  level of 
activation/exposure - when clinically feasible –  and reintroduction of its use (or increase of the 
level of activation/exposure) , do not impact on the serious event;  
− the event involves a body- site or an organ not expected to be affected  by [CONTACT_484531];  
− the serious event can be attributed to another cause (e.g. an underlying or concurrent illness/ 
clinical condition, an effect of another d evice,  drug, treatment or other risk factors) . 
• Unlikely : the relationship with the use of the device  seems not relevant and/or  the event can be 
reasonably explained by [CONTACT_5748], but additional  information may be obtained.  
• Possible:  the relationship with the use of the investigational device is weak but  cannot be ruled out 
completely.  Alternative ca uses are also possible (e.g. an  underlying or concurrent illness/ clinical 
condition or/and an effect of another  device, drug or treatment).  Cases were rel atedness cannot be 
assessed or no  information has been obtained should also be classified as possibl e. 
• Probable : the relationship with the use of the investigational device seems  relevant and/or the 
event cannot reasonably be explained  by [CONTACT_5748], bu t additional information may be 
obtained.  
• Causal relationship: the serious event is associated with the investigational device or with 
procedures beyond reasonable doubt when:  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October 31 , 2018 
  23 − the event is a known side effect of the product category the device belongs to o r of similar 
devices and procedures;  
− the event has a temporal relationship with investigational device use/application or procedures;  
− the event involves a body- site or organ that the investigational device or procedures are applied 
to or the investigationa l device or procedures have an effect on; 
− the serious event follows a known response pattern to the medical  device (if the response 
pattern is previously known);  
− the discontinuation of medical device application (or reduction of the level of 
activation/exp osure) and reintroduction of its use (or increase of the  level of 
activation/exposur e), impact on the serious event (when clinically feasible);  
−  other possible causes (e.g. an underlying or concurrent illness/ clinical  condition or/and an 
effect of another  device, drug or treatment) have  been adequately ruled out;  
− harm to the subject is d ue to error in use;  
8.2.3  EXPECTEDNESS  
Expected  (anticipated)  adverse reactions are AEs that are common and known to occur for the 
investigational device being  studied.   Expected adverse events in this study include discomfort or 
significant pain post -treatment , excessive skin redness (erythema) and/or swelling (edema) , in-grown 
hairs , damage to natural skin texture (crust, blister, burn) , change of pi[INVESTIGATOR_371] (hyper - and hypo -
pi[INVESTIGATOR_371]) , scarring . Treatment of hair -bearing areas in males may result in some damage to the 
follicles and subsequent loss of hair.   
An AE or suspected adverse reaction is considered "unexpected"  (unanticipated) if it is not known to 
occur for the investigational device being  studied and at the specificity or severity that has been 
observed (AE not described into the Clinical protocol  or User Manual ). 
8.3 TIME PERIOD AND FREQ UENCY FOR EVENT ASSESSMENT AND FOLLOW -UP 
The occurrence of an AE or SAE  may come to the attention of study personnel during study visits and 
interviews of a study participant presenting for medical care, or upon review by a study monitor.  All AEs 
including local and systemic reactions not meeting the criteria for SAEs will be captured on the 
appropriate CRF.  Information to be collected includes event description, time of onset, clinician’s 
assessment of severity, relationship to investigat ional device and study procedures (assessed only by 
[CONTACT_484532] a diagnosis), and time of resolution/stabilization of the 
event.  All AEs occurring while on study must be documented appropriately regardless of relationship. 
All AEs will be followed to adequate resolution.  
Any medical condition that is presen t at the time that the participant is screened will be considered as 
baseline and not reported as an AE. However, if the study participant’s condition deteriorates at an y 
time during the study, it will be recorded as an AE.  
Changes in the severity of an AE  will be documented to allow an assessment of the duration of the event 
at each level of severity to be performed.  AEs characterized as intermittent require documentati on of 
onset and duration of each epi[INVESTIGATOR_1865].  
The PI [INVESTIGATOR_484519].  At each study visit, the investigator will inquire study subjects about the occurrence of 
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October 31 , 2018 
  24 AE/SAEs since the last visit. All adverse events need to be followed until r esolution or until study end, 
whichever occurs first . 
8.4 REPORTING PROCEDURES  
 
8.4.1  ADVERSE EVENT REPORT ING  
All AEs will be recorded on the appropriate CRF and will include information about the start and stop 
dates, severity and relatedness.  There should be an attempt to repor t a “diagnosis” rather than the 
individual signs, symptoms and abnormal laboratory values associated with the diagnosis. However, a 
diagnosis should be reported only if, in the Investigator’s judgment, it is relatively ce rtain (i.e., definite 
or possible).  Otherwise individual signs, symptoms and abnormal laboratory values should be reported 
as distinct  adverse events.  
8.4.[ADDRESS_622782] be reported to the  sponsor’s 
clinical research department immediately or within 24 hours  by [CONTACT_10399]  (see contact 
[CONTACT_2212]).  
Name: [CONTACT_484543], Clinical Research Manager  
Phone: 888 -907-0115 ext. 127 
Email: [EMAIL_9329] m 
Address: [ADDRESS_622783], Toronto, Ontario, Canada, M2J 1R4  
A written report prepared by [CONTACT_079] (or designate ) must follow within seven working 
days to the clinical monitor and should include a full description of the event a nd sequence.  
The study investigator  shall complete a Serious Adverse Event  / Serious Adverse Device Effect Form and 
submit to the study sponsor as soon as possible, but in no event later than [ADDRESS_622784].  
In accordance with the requireme nts of Directive 93/42/EEC, and with MEDDEV 2.7/3, the following 
events are considered reportable events: 
1. any SAE (whether or not study  procedure or device related),  
2. any Investigational Medical Device Deficiency that might have led to a SAE if a) suitable action 
had not been taken or b) intervention had not been made or c) if circumstances had been less 
fortun ate, 
3. new findings/updates in relation to already reported events.  
 
The sponsor will report the above -mentioned  events to the Compete nt Authorities of all countries 
where the study is being conducted, within the following timelines:  
− Any SAE which indicates an imminent risk of death, serious injury, or serious illness AND that 
requires prompt remedial action for other patients/subjects, users or other per sons or a new 
finding to it: immediately, but not later than 2 calendar days after awareness by [CONTACT_10400]  a 
new reportable event or of new information in relation with an already reported event.  
− Any other reportable event or a new finding / update to it: immediately, but not later than 7 
calendar days following the date of awareness by [CONTACT_41493].  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October 31 , 2018 
  25  
Reporting of the events listed above (under bullets 1 -3) to the EC s of the participating sites and to the 
other investigators will be performed according to country and/or site -specific  requirements. 
 
8.4. [ADDRESS_622785] or Partner Pregnancy Outcome form within  10 business days.  
8.5 STUDY HALTING RULES  
The study may be halted at any time by [CONTACT_456], the EC / IRB, Competent Authorities due  to sa fety 
concerns.  Examples of findings that might trigger a safety review are the number of SAEs overall, the 
number of occurrences of a particular type of SAE, severe AEs/reactions, or increased frequency of 
events.   If the study is halted, the sponsor will  immediately notify  all investigational sites, the EC / IRB(s), 
the Competent Authorities of all countries where the study is being conducted.  
8.6 SAFETY OVERSIGHT  
Independent oversight is an important component to ensure human subjects' protection.  Safet y 
oversight will be under the direction of the sponsor and a medical monitor.  
8.7 TRAINING REQUIREMEN TS  
Prior to patients’ enrollment, the Sponsor will provide training relevant and pertinent to the involvement of personnel conducting study activities. Tr aining for investigators and staff will include 
study -specific protocol and CRF completion training by [CONTACT_3433] e sponsor or designate and on -site training on 
the use of the investigational device by [CONTACT_456].  Evidence of training will be documented during th e 
site initiation visit and by [CONTACT_10403] a device training certificate.  
[ADDRESS_622786] of 
the trial is in compliance with the currently appro ved protocol/amendment(s), with GCP, and with 
applicable regulatory requirement(s).  
• Monitoring for this study will be performed by [CONTACT_10404].  
• On-site  monitoring will occur within [ADDRESS_622787] and will occur at a 
frequenc y described in the Monitoring Plan. 
• Variables to be monitored will be described in the Monitoring Plan.  
• The Study Director or designate will be provided copi[INVESTIGATOR_10376] 15 business 
days of visit.  
 
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October 31 , 2018 
  26 10 STATISTICAL CONSIDER ATIONS   
 
10.1  STATISTICAL AND ANALYT ICAL PLANS 
The Statistical and Analytical Plans (SAP) may be revised during the study to accommodate Clinical Trial 
Protocol Amendments and to make changes to adapt to unexpected issues in study execution and data 
that affect planned analyses. If revised, a formal St atistical and Analytical Plans (SAP) will be completed 
and issued  prior to database lock and unblinding of the study data.   
10.2  STATISTICAL HYPOTHES ES 
The null and alternative hypotheses for the study’s primary, key secondary and safety endpoints are;  
• Primary Efficacy Endpoint:  
Null Hypothesis (H o: µd = µpost – µpre = 0) – There is no improvement in acne scarring at 6-week an d 
12-week  post -treatment compared to baseline as assessed by [CONTACT_484533] (GAIS).  
 
Alternative Hypothesis (Ha: µd = µpost – µpre ≠ 0)  – There is an Improvement in  acne scar ring at 6-
week and [ADDRESS_622788] -treatment compared to baseline as assessed by [CONTACT_484534] (GAIS). The efficacy 
endpoint improvement is defined as a score  of > 0.75 on the Global  Aesthetic Improvement Scale 
(GAIS). This is the e xpected mean difference in GAIS score at [ADDRESS_622789] -treatment 
assessment compared to baseline.   
 
• Secondary Efficacy Endpoint(s):  The following Null Hypotheses (H
o: µd = µpost – µpre = 0) - There is no improvement in subjects’ 
assessment of satisfaction with the treatment using a Subject Satisfaction Scale at [ADDRESS_622790] -treatment.  
 
The following Alternative Hypotheses (Ha: µd = µpost – µpre  ≠ 0) - There is an improvement in 
subjects’ assessment of satisfaction with the treatment using a Subject Satisfaction Scale  at [ADDRESS_622791] -treatment.  
 
• Safety Endpoint : 
Null Hypothesis (H o: µd = µpost – µpre = 0) – There is no difference in subjects’ 10 cm discomfort/pain 
VAS score and Tolerability Scale experienced at Visit 3 treatment compared to that which was 
experienced at baseline treatment (Visit 1).  
 
Alternative Hypothesis (H a: µd = µpost – µpre ≠ 0)  – There is a difference in subjects’ 10 cm 
discomfort/pain VAS score and Tolerability Scale experienced at Visit 3 treatment compared to that which was experienced at baseline treatment (Visit 1) . 
 
10.3  ANALYSIS DATASETS  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October 31 , 2018 
  27 Modified Intention-to -Treat A nalysis Dataset will be used; Efficacy and safety analyses will be carried out 
on all subjects who received at least one treatment of Venus Viva™ fractional RF device  and for whom at 
least one valid post -baseline efficacy and s afety evaluation were obtaine d.  
10.4  DESCRIPTION OF STATISTICAL METHODS  
 
10.4.1  GENERAL APPROACH  
This is prospective, single centre, evaluator -blind study of the safety and performance of fractional 
radiofrequency (RF) for the treatment and reduction of acne scarring.  
All summary ta bles for quantitative parameters will display mean, standard deviation, median, range 
(minimum and maximum), percentages as well as number of missing data (if relevant). All summary tables 
for qualitative paramete rs will display counts, percentages and num ber of missing data if relevant. 
Baseline data are defined as the last measurement , photograph or assessment performed before the first 
treatment on Visit 1 .  
All statistical tests will be two -sided. The level of statistical significance for effectiveness analyses is 5% (α 
= 0.05) for all tests of differences. Where appropriate, Paired t -test and/or Wilcoxon Signed -Ranks Test 
for Matched Pairs will be used to compare the evaluations at the baseline and post treatme nt sessions. 
This test will enable us to ac cept or reject the null hypotheses. Rejection of null hypotheses will establish 
that:  
• The two -sided 95% confidence interval for the difference between the means excludes zero.  
• The two means are statistically signi ficantly different at the 5% level ( P < 0.0 5) two -sided.  
Upon rejection of null hypotheses, further statistical test tools such as Confidence Interval and/or t -test 
will be used to determine the efficacy of the treatment.  
In other to accommodate imbalances  of some baseline GAIS  score s, covariate ad justment analysis may be 
performed in SAP to estimate adjusted treatment effects for the primary endpoint analysis.  
The assumption for the statistical test is that the paired differences of baseline and post treat ment data 
are normally distributed  
10.4.2  ANALYSIS OF THE PRIMARY EFFICACY ENDPOINT(S)  
The following will be considered for the analysis primary endpoint:  
Summary table for differences of baseline compared to  6-week and baseline compared to  12-week post -
treatment  GAIS  score s will be displayed as mean difference, standard deviation and standard error.  The 
Global Aesthetic Improvement Scale (GAIS) is an ordinal scale tool that can be used to assess reduction of 
acne scarring.  
 
Bar, pie charts or graph s indicating scores, percentages or proportions of  subjects with Global Aesthetic 
Improvement Scale (GAIS).  
 All statistical tests will be two -sided. The level of statistical significance for effectiveness analyses is 5% (α 
= 0.05) for all tests of differences. Where appropriate, Paired t -test and/or Wilc oxon Signed -Ranks Test 
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October [ADDRESS_622792] treatment assessment s. Analysis of Covariance (ANCOVA) may also be used 
where appropriate. Since the primary endpoint is based on achieving a fixed scale point on the GAIS, 
covariate adjustment analysis may be performed in SAP to estimate adjusted treatment effects for the 
primary endpoint analysis  in covariate adjustment analysis may be performed in SAP to estimate adjusted 
treatment effects for the primary endpoint anal ysis.   
The Paired t -test and/or Wilcoxon Signed-Ranks Test for Matched Pairs will enable us to accept or reject 
the null hypotheses. Rejection of null hypotheses will establish that: 
• The two -sided 95% confidence interval for the difference between the means excludes zero. 
• The two means are statistically significantly different at the 5% level ( P < 0.05) two -sided.  
Upon rejection of null hypotheses, further statistical test tools such as Confidence Interval and/or t -test 
will be used to test expected primary  endpoint; that is alternative hypothesis that H a > 0.75 . This will be 
used to determine if the study meet s the primary endpoint ; GAIS  score of > 0.[ADDRESS_622793] one treatment of Venus Viva™ fractional RF device  and for 
whom at least one valid post -baseline GAIS assessment were  obtained  will be analysed for the primary endpoint . 
Multiple imputation  method or modelling of available da ta may be used for missing data as 
appropriate.  
10.4.3  ANALYSIS OF THE SECO NDARY ENDP OINT(S)  
For the analysis of secondary endpoints, the following analysis will be considered:  
Summary tables for differences of baseline compared to  6-week and baseline compared to  12-week post -
treatment  of subjects’ assessment of satisfaction with the treat ment using a Subject Satisfaction Scale  will 
be displayed as mean difference, standard deviation and standard error.  The point level for each of these 
ordina l scale assessment tools will be put into consideration where applicable.  
 
Bar charts, pie chart, graphs or any other descriptive statistical displays indicating scores, percentages or 
proportions of Subjects’ assessment of satisfaction with the treatment using a Subject Satisfaction Scale 
will be used to analyse efficacy.  
 
All statistical tests that w ill be two -sided. The level of statistical significance for effectiveness analyses is 
5% (α = 0.05) for all tests of differences. Where appropriate, Paired t -test and/or Wilcoxon Signed- Ranks 
Test for Matched Pairs will be used to compare the evaluations s core differences of baseline compared to  
6-week and baseline compared to  12-week  post treatment assessment. Analysis of Covariance (ANCOVA) 
may also be used w here appropriate.  
Subjects’ assessment of satisfaction with the treatment using a Subject Satisfa ction Scale  of all subjects 
who received at least one treatment of Venus Viva™ fractional RF device  and for whom at least one valid 
post -baseline assessment w ere obtained will be analysed for these secondary endpoints. Multiple 
imputation  method or modell ing of available data may be used for missing data as appropriate.  
10.4.4  SAFETY ANALYSES  
The safety analysis will be done by [CONTACT_10407]  (AE), subjects ’ 
complete d 10 cm discomfort/pain VAS and Tolerability Scale as well as analysis of immediate and short 
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October 31 , 2018 
  29 term response reports by [CONTACT_458] [INVESTIGATOR_484520]/her observation/examination of the treated 
area. Appropriate Medical Dictionary for Regulatory Activities (MedDRA ) code will be used to describe all 
spontaneou sly report ed or other study related  adverse events . 
Summaries of spontaneous ly report ed or other study related  adverse events  will be presented as : 
o Number (%) of subject s with any AE,  
o Number (%) of subject s with any  serious adverse events (SAE), 
o Number (%)  of subject s permanently wit hdrawn from treatment due to AE  
Summaries of analy sis of immediate and short term response  reports by [CONTACT_458]  
[INVESTIGATOR_10378] a  bar or pie chart as;  
o the overall frequency of subject s with eac h event (pain during treatment, hemorrhage, burn, 
erythema, edema, purpura)  
o Frequency of subject s with specific severity/ intensity for each event  using a 5 points scale: 
1=none; 2=trace; 3=moderate; 4=marked; 5=severe  
o The overall percentage  or proportion of subject observed with marked or severe intensity of any 
event will be calculated and compared to those with none, trace or moderate severity/intensity 
with the aid of a bar or pie chart.  
The following will be considered for the analysis of 10 cm discomfo rt/pain VAS scores   safety data:  
Summary table for differences of baseline and Visit 3  treatment 10 cm discomfort/pain VAS scores   will 
be displayed as mean difference, standard deviation and standard error.  The 10 cm  discomfort/pain VAS  
is a 11-level (0 to 10) ordinal scale tool for assessing pain.  
 
Bar, pie charts or graphs indicating scores, percentages or proportions of subjects with Visit 3 treatment 
and baseline  (Visit 1) VAS scores  difference and Tolerability Scale will be used to analyse subjects’ 
tolerability of this treatment . 
 All statistical te sts will be two -sided. The level of statistical significance for effectiveness analyses is 5% (α 
= 0.05) for all tests of differences. Where appropriate, Paired t -test and/or Wilcoxon Signed -Ranks Test 
for Matched Pairs will be used t o compare the difference  between baseline and Visit [ADDRESS_622794] and/or Wilcoxon Signed-Ranks Test for Matched Pairs will enable us to accept or reject 
the null hypotheses. Rejection of null hypotheses will establish that: 
• The two -sided 95% confiden ce interval for the difference between the means excludes zero.  
• The two means are statistically significantly different at the 5% level ( P < 0.05) two -sided.  
Upon rejection of null hypotheses, further stat istical test tools such as Confidence Interval and/or t -test  
will be used to test expected safety endpoint; that is alternative hypothesis,  Ha < 1.  
10.4.5  ADHERENCE AND RETENTION ANALYSES  
Adherence to the protocol will be assessed  by [CONTACT_10408] (%) subjects’ data for each endpoint 
assessment that is not provided in subjects Case Report Forms. This will be further analysed as per 
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October 31 , 2018 
  30 frequency of each endpoint data that is not available due to l oss to follow -up, discontinuat ion of the 
intervention or any other reason . 
 
10.4.6  BASELINE DESCRIPTIVE  STATISTICS  
Subjects baseline scores of all endpoints (GAIS, Subject Satisfaction Scale, Treatment Evaluation 
Questionnaire, VAS and Tolerability Scale) will be compared using  descri ptive statistics  such as mean 
score, standard deviation, standard error, range and graphical presentations.  
10.4.7  PLANNED INTERIM ANAL YSES  
N/A - There will be no interim analysis during this study.  
 
[IP_ADDRESS]  SAFETY REVIEW  
There will be no interim analys is during this study . How ever, t his study may be temporarily suspended or 
prematurely terminated if there is sufficient reasonable cause  as per section 5.5 and 8.5.  
[IP_ADDRESS]  EFFICACY REVIEW  
There will be no interim analysis during this study. However, t his study may be temporaril y suspended 
or prematurely terminated if there is sufficient reasonable cause  as per section 5.5 and 8.5.  
10.4.8  ADDITIONAL SU B-GROUP ANALYSES  
Not Applicable - Primary or secondary endpoint will not be analyzed based o n age, sex, race/ethnicity or 
other d emographic characteristic(s).  
10.4.9  MULTIPLE COMPARISON/ MULTIPLICITY  
Not Applicable   
10.4.10  TABULATION OF INDIVIDUAL RESPONSE DATA  
Individual participant data will be listed by [CONTACT_484535] t he study report . 
10.4.11  EXPLORATORY ANALYSES  
Not Applicable   
10.5  SAMPLE SIZE  
The primary endpoints outcome measures w as used to calculate the study sample size.  
Sample size calculation using primary endpoint outcome measure;  
• Null and alternate hypotheses:  
o Null Hypothesis (H o: µd = µpost – µpre = 0) – There is no improvement in acne scarring at [ADDRESS_622795] -treatment compared to baseline as assessed by [CONTACT_484536] F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October 31 , 2018 
  31 evaluators by [CONTACT_484537] 
(GAIS).  
 
o Alternative Hypothesis (Ha: µd = µpost – µpre ≠ 0)  – There is an Improvement in  acne scarring 
at 6-week and [ADDRESS_622796] -treatment compared to baseline as assessed by [CONTACT_484538] 
(GAIS). The efficacy en dpoint impr ovement is defined as a score  of > 0.75  on the Global 
Aesthetic Improvement Scale (GAIS). This is the e xpected mean difference  in GAIS score 
at 6-week and [ADDRESS_622797] -treatment assessment compared to baseline.  
• In view of the nature of this stu dy in regard to treatment and follow -up duration , we make 
provision for 55% study drop out, withdrawal or loss to follow-up.  
• 2- Tailed Sample Size calculation formula for Matched Samples  was used in the table below:  
 
(1-β), Power  0.8 
α, Level of Significance  0.05  
μd, mean difference; this is the smallest possible change 
expected under H a 0.[ADDRESS_622798] Deviation of the difference scores (GAIS 
range ÷ 4) = [6 ÷ 4]  1.5 
Z1-α/2 1.96  
Z1-β, (for 90%)  0.84  
Estimated Sample Size   32 
Estimated Sample Size + 55% drop out  50 
Conclusion:  The estimated sample size for treatment site and the additional 55% provision for drop out 
(50 treatment sites ) obtained from the primary endpoint outcome measure calculation will be us ed for 
this study.   25 subjects will undergo treatment on 2 different sites; one on each side of the face that will 
be will be assessed independently as two separate sites.  
10.6 MEASURES TO MINIMIZE BIAS  
 
10.6.1  ENROLLMENT/ RANDOMIZ ATION/ MASKING PROCE DURES  
At screening, once a subject has signed the informed consent, and inclusion/exclusion criteria has been 
met, a subject number will be assigned. The subject number will consist of a two -digit code corresponding 
to the site and a two digit subject code in n umerical sequence. (Example: 10 -05 corresponds to site #10, 
subject #5.)  
10.6.[ADDRESS_622799] s will receive acne scar treatment .   
10.6.3  BREAKING THE STUDY B LIND/ PARTICIPANT  CODE  
N/A - All subject s will receive acne scar treatment . 
 
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October 31 , 2018 
  32 11 SOURCE DOCUMENTS AN D ACCESS TO SOURCE D ATA/DOCUMENTS  
Each participating site will maintain appropriate medical and research records for this trial, in 
compliance with ISO [ZIP_CODE]:2011, and regulatory and institutional requirements fo r the  protection of 
confidentiality of participants. Each site will permit authorized representatives of the study sponsor , 
ethics  committee  and/or regulatory agencies to examine (and when permitted by [CONTACT_1289], to 
copy) clinical records for the purp oses of quality assurance reviews, audits, and evaluation of the study 
safety, progress, and data validity.  
Source data are all information, original records of clinical findings, observations, or other activities in a 
clinical trial necessary for the rec onstr uction and evaluation of the trial. Examples of these original 
documents and data records include, but are not limited to, hospi[INVESTIGATOR_1097], clinical and office charts, 
laboratory notes, memoranda, participants' memory aids or evaluation checklists, p harma cy dispensing 
records, recorded audio tapes of counseling sessions, recorded data from automated instruments, 
copi[INVESTIGATOR_10379], microfiches, 
photographic negatives  (where  applicable) , micr ofilm or magnetic media, x -rays, and participant files 
and records kept at the pharmacy, at the laboratories, and medico -technical departments involved in 
the clinical trial.  
It is acceptable to use CRFs as source documents.  The following CRFs colle cted on no carbon required 
(NCR) paper will be source documents:  
• Subject self -reported VAS and Tolerability Scale, GAIS  and Subject Satisfaction Scale , Treatment 
Evaluation  
The remainder of the data  collected from other sources.  
It is no t acceptable for the CRF to  be the only record of a subject’s  participation in the study. This is to 
ensure that anyone who would access the patient medical record has adequate knowledge that the 
patient is participating in a clinical trial.  
12 QUALITY ASSURANCE AND QUALITY CO NTROL  
Prior to any independent use of the Venus Viva ™ applicator device, study personnel, will receive proper 
training from the sponsor. Site personnel will be trained on the use of the device prior to study initiation 
at the site.  Additional  training requi rements will be discussed during study initiation and will include site 
responsibilities, and study documentation. In addition, the sponsor will provide protocol specific training 
for the site. The site will document which individu al has been assigned to a specific task and will ensure 
that appropriate training has occurred for that task.  
Regular monitoring and an independent audit, if conducted, must be performed according t o ISO 
[ZIP_CODE]:2011. See also Section 9, Clinical Monitoring . 
Quality control (QC ) procedures will be implemented beginning with the data entry system and data QC 
checks that will be run on the database will be generated.  Any missing data or data anomalies will be 
communicated to the site(s) for clarification/resol ution.  
Monitors will verify that the clinical trial is conducted,  and data are generated, documented (recorded), 
and reported in compliance with the protocol, GCP, and the applicable regulatory requirements.  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October [ADDRESS_622800] access to all trial related sites, source data/documents, and 
reports for the purpose of monitoring and auditing by [CONTACT_456], and inspection by [CONTACT_10412].  
13 ETHICS/PROTECTION OF  HUMAN SUBJECTS  
 
13.[ADDRESS_622801] version of the 
Declaration of Helsinki (2013), ISO [ZIP_CODE]:2011 (Clinical investigation of medical devices for human 
subjects - Good clinical practice) , FDA and any o ther applicable country’s  ethical policy statement, 
whichever provides the higher level of  protection to human subjects.  
13.2 ETHICS COMMITTEE AND  COMPETENT AUTHORITIES   
The protocol, informed consent form(s), recruitment materials, and all participant mat erials will be 
submitted to the EC / IRB for review and approval. Approval of both the protocol and the consent form 
must be obtained before any participant is enrolled. Any amendment to the protocol will require review 
and approval by [CONTACT_1383] / IRB before the changes are implemented to the stu dy. All changes to the 
consent form will be EC / IRB approved; a determination will be made by [CONTACT_10413]-consented.  
13.3 INFORMED CONSENT PRO CESS  
 
13.3.1  CONSENT/ASSENT AND OTHER INFORMATIONA L DOCUMENTS PROVIDED TO 
PARTICIPANT S 
Informed consent is required for all subjects in a study.  In obtaining and documenting informed 
consent, the investigator should comply with applicable regulatory requirements and should adhere to 
ISO [ZIP_CODE]:[ADDRESS_622802] version of the Declaration of Helsinki (2013) .  Prior to th e beginning of 
a trial, the investigator should have the EC / IRB's written approval for the protocol and the written 
informed consent forms(s) and any other written information to be p rovided to the participants.  
Consent forms describing in detail the investigational medical device , study procedures, and risks are 
given to the participant and written documentation of informed consent is required prior to starting 
intervention with  investigational medical device . 
13.3.2  CONSENT PROCEDURES AND D OCUMENTATION 
Informed consent is a process that is initiated prior to the ind ividual’s agreeing to participate in the 
study and continues throughout the individual’s study participation. Extensive discussion of risks and 
possible benefits of participation will be provided to the participants and their families.   Consent forms 
will be EC or IRB approved and the participant will be asked to read and review the document. The 
investigator will explain t he research study to the participant and answer any questions that may arise. 
All participants will receive a verbal explanation in term s suited to their comprehension of the purposes, 
procedures, potential risks of the study and their rights as research p articipants.   Participants will have 
the opportunity to carefully review the written consent form and ask questions prior to signing. Th e 
participants should have the opportunity to discuss the study with their surrogates or think about it 
prior to agreeing to participate.  The participant will sign the informed consent document prior to any 
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October [ADDRESS_622803] by [CONTACT_3486], their staff, and the 
sponsor(s) and their agents . This confidentiality is extended to cover testing of biological samples in 
addition to the clinical information relating to participants. Therefore, the study protocol, 
documentation, data, a nd all other information generated will be held in strict confidence. No 
information concerning the study or the data will be released to any unauthorized third party without 
prior written approval of the sponsor.  
The study monitor, other authorized repres entatives of the sponsor, representatives of the EC / IRB and  
Competent Authorities or device  company supplying study product may insp ect all documents and 
records required to be maintained by [CONTACT_093], including but not limited to, medical records  
(office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the participants in this study. The clinical study site will permit access to such records.  
The study participant’s contact [CONTACT_10414]. At the end of the study, all records will continue to be kept in a secure location for as long a period as dictated b y the sponsor,  and any applicable regulations  (refer to section 14.2 STUDY 
RECORDS RETENTION ). 
Study participant research data, which is for purposes of statistical analysis and scientific reporting, will be transmitted to and stored at the sponsor’s offic e. This will not include the participant’s contact [CONTACT_10415]. Rather, individual participants and their r esearch data will be identified by a 
unique study identification number. The study data entry and study management systems used by 
[CONTACT_100977]’s research staff will be secured and password protected.  At the end of the 
study, all study da tabases will be de -identified and archived by  [CONTACT_456] . 
13.4.[ADDRESS_622804] KEEPI[INVESTIGATOR_484521] F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October [ADDRESS_622805] eted in a neat, legible manner to ensure accurate interpretation 
of data.  Black ink is required to ensure clarity of reproduced copi[INVESTIGATOR_014]. When making changes or 
corrections, cross out the original entry with a single line, and initial and date the change.  DO NOT 
ERASE, OVERWRITE, OR USE CORRECTION FLUID OR TAPE ON THE ORIGINAL.  
Copi[INVESTIGATOR_10380].  Data reported in the CRF derived f rom source documents 
should be consistent with the source documents or the discrepancies should be exp lained and captured 
in a progress note and maintained in the participant’s official study record.   Self-reported subject data  
and investigator CRF reported data  recorded on the copy CRF page is permitted.  The original form will 
be collected by [CONTACT_484539].  
Clinical data (including AEs, concomitant medications, and expected adverse reactions data) and clinical 
laboratory  data from paper CRFs will be entered directly onto paper CRFs from the source documents 
and will be c ollected by [CONTACT_4530]. 
14.2 STUDY RECORDS RETENT ION  
Study documents , including copi[INVESTIGATOR_10381], signed informed consent forms, photograp hs 
(where  applicable) , laboratory results, medical records , data clarification forms and regulatory 
documents,  should be retained for a minimum period of [ADDRESS_622806] udy related materials .  No records will be destroyed without the 
written consent of the sponsor, if applicable.  It is the responsibility of the sponsor to inform the 
inves tigator when these documents no longer need to be retained. 
14.3 PROTOCOL DEVIATIONS   
A protocol deviation is any instance(s) of failure to follow, intentionally or unintentionally, the 
requirements of the Clinical Investigation Plan. Applicable definition follow: 
− Major deviation: CIP deviations that can have affected the rights, safety o r well- being of the subject 
or the scientific integrity of the clinical investigation.  
− Minor deviation: CIP deviations that do NOT have affected the rights, safety or well -being of the 
subject or the scientific integrity of the clinical investigation.  
The noncompliance may be either on the part of the participant, the investigator, or the study site staff.  
As a result of deviations, corrective actions are to be developed by  [CONTACT_3483].  
These practices are consistent with ISO [ZIP_CODE]:2011:  
• 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3  
• 5.1 Quality Assurance and Quality Control, section 5.1.1  
• 5.20 Noncompliance, sections 5.20.1, and 5.20.2.  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October [ADDRESS_622807] been met:  
a. The Investigator, the Sponsor and Statistician have approved the protocol amendment and  
b. The responsible EC and Competent Authority has reviewed an d approved the protocol change.  
Under emergency circumstances, deviations from the CIP to protect the ri ghts, safety and well -being of 
human subjects may proceed withou t prior approval of the sponsor and the EC.  Such deviations shall be 
documented and reported to the sponsor and the EC as soon as possible.  
A corrective action will be taken: documenting the  deviation (source document, log, CRF as relevant) 
including its  reasons of occurrence and corrective actions to be taken to further avoid reoccurrence of it 
and properly reporting. The investigator as well as site personnel will be trained in order to avo id any 
major protocol deviation in the future.  
Failure to comply  with this clinical investigation plan and/or EC, Competent Authorities, any local 
requirement will result in corrective actions and could result in the removal of the investigator from the 
study.  
It is the responsibility of the site to use continuous vigi lance to identify and report deviations  promptly 
to study sponsor and to EC (if required by [CONTACT_1295] ).  All deviations must be addressed in study 
source documents.  The site PI/study s taff is responsible for knowing and adhering to their EC 
requirements .  
14.4 PUBLICATION AND DATA SHARING POLICY  
The International Committee of Medical Journal Editors (ICMJE) member journals have adopted a clinical trials registration policy as a conditio n for publication. The ICMJE defines a clinical trial as any 
research project that prospectively assigns human subjects to intervention or concurrent comparison or 
control groups to study the cause-and -effect relationship between a medical intervention and a health 
outcome. Medical interventions include drugs, surgical  procedures, devices, behavioral treatments, 
process -of-care changes, and the like.  Health outcomes include any biomedical or health-related 
measures obtained in patients or participants and adverse events. The ICMJE policy, and the  Section [ADDRESS_622808] of 2007, requires that all clinical trials be 
registered in a public trials registry such as ClinicalTrials.gov, which is sponsored by [CONTACT_10418]. Other biomedical journals are considering adop ting similar policies.  The Decla ration of 
Helsinki current revision (2013) states that every research study involving human subjects must be registered in a publicly accessible database befor e recruitment of the first subject (sec.35).  
The sponsor or its designee  will register the
 VI1018 study into a publicly accessible database .  All data 
generated from this study are the property of Venus Concept Ltd and shall be held in strict confidence 
along with all information furnished by [CONTACT_484540] . 
Independent analysis and/or publication of these data by [CONTACT_10420]/her staff are not permitted without prior written consent of Venus Concept Ltd.   Written permission to the 
Investigator will be contingent on the revi ew by [CONTACT_484541]. In all cases, the parties agree to submit all manuscripts or a bstracts to all other parties at 
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October [ADDRESS_622809].  
17  LITERATURE REFER ENCES  
1. O'Daniel TG. Multimodal management of atrophic acne scarring in the aging face. Aesthetic Pla st 
Surg. 2011; 35(6):1143-50.  
2. Simmons B, Griffith R, Falto -Aizpurua L, Nouri K.  Use of radiofrequency in cosmetic dermatology: 
focus on nonablative treatment of acne scars. Clinical, Cosmetic and Investigational Dermatology. 
2014:7 335— 339 
3. Alster TS, Lupt on JR. Nonablative cutaneous remodeling using radiofrequency devices . Clin 
Dermatol. 2007; 25:487-491.  
4. Alexiades -Armenakas M, Dover JS, Arndt KA. Unipolar versus bipolar radiofrequency treatment of 
rhytides and laxity using a mobile painless delivery metho d. Lasers Surg Med. 2008;40(7):446-453 
5. De Felipe I, Del Cueto SR, Pérez E, Redondo P. Adverse reactions after nonablative radiofrequency: follow -up of 290 patients. J Cosmet Dermatol. 2007;6(3):163-166.  
6. Omi T, Sato S, Kaminaka C, Yamamoto Y, Kawana S, et al. (2014) A Histological Study on the 
Treatment of Acne Scars with Fractional Radiofrequency: Preliminary Findings. J Clin Exp Dermatol 
Res 5:203  
7. E. Forbat & F. Al -Niaimi (2016)  Fractional radiofrequency treatment in acne scars: Systematic 
review of current evidence,  Journal of Cosmetic and Laser Therapy, 18:8, 442-447 
  
Clinical Evaluation of the Safety and Performance of F ractional Radiofrequency for the Treatment and Reduction of Acne 
Scarring  Version 1.0 
Protocol #VI1018  October [ADDRESS_622810]  
ISO [ZIP_CODE]:2011  International Organization for Standardization Good Clinical Practices for Clinical 
Investigations of Medical Devices  
MedDRA  Medical Dictionary for Regulatory Activities  
PI [INVESTIGATOR_484522]  
 